Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly & Co. Director Ralph Alvarez acquired 14.525 shares of common stock by deferring cash compensation under the company's Directors' Deferral Plan.

Summary

• Ralph Alvarez, a Director of Eli Lilly & Co. (LLY), acquired 14.525 shares of common stock.
• The acquisition occurred on October 20, 2025, at a price of $808.96 per share.
• These shares were acquired through the deferral of cash compensation, converted into stock units under the Lilly Directors' Deferral Plan.
• The stock units will be settled in shares of common stock following Alvarez's separation from service.
• Following this transaction, Alvarez directly owns 55,151.946 shares and indirectly owns 758 shares through a trust.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director through compensation deferral is generally a positive signal, indicating confidence in the company's future. It's a routine transaction but still reflects insider belief.

Positives

• Director Ralph Alvarez's election to defer cash compensation into company stock demonstrates confidence in Eli Lilly & Co.'s future performance.
• The deferral plan aligns the director's long-term interests with those of shareholders.

Risks

• The value of the deferred stock units is subject to market fluctuations of Eli Lilly & Co. common stock until settlement.

Future Outlook

The filing indicates a long-term commitment from a director through a compensation deferral plan, suggesting an expectation of continued value appreciation for Eli Lilly & Co. common stock.

Management Comments

• The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

This type of insider transaction, where directors defer cash compensation into company stock, is a common practice in the pharmaceutical industry and other sectors. It is generally viewed as a positive signal, indicating management's belief in the company's long-term prospects and aligning their financial interests with shareholders.

Comparison to Industry Standards

• Deferring compensation into company stock is a standard corporate governance practice across various industries, including pharmaceuticals. Companies like Pfizer, Johnson & Johnson, and Merck also offer similar director compensation deferral plans to encourage long-term alignment.
• The specific value of the shares acquired ($808.96 per share) reflects Eli Lilly's current market valuation, which is competitive within the large-cap pharmaceutical sector, often compared to peers like Novo Nordisk or AstraZeneca based on market capitalization and growth prospects.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction signals director confidence, potentially reinforcing investor sentiment. It also aligns director incentives with long-term shareholder value.

Next Steps

• Settlement of the acquired stock units in shares of common stock will occur following the reporting person's separation from service.

Key Dates

Recommendation

This Form 4 filing indicates a routine insider transaction where a director defers cash compensation into company stock. While it signals confidence from management, it does not present new fundamental information or a significant change in the company's operational or financial outlook that would warrant a change in investment recommendation. It reinforces a 'hold' position for investors already invested, as it suggests continued alignment of director interests with long-term shareholder value, but it's not a catalyst for a 'buy' or 'sell' decision on its own.

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Director Compensation, Stock Deferral, Ralph Alvarez, Common Stock